PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463775
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463775
Market Overview
The worldwide gastrointestinal stent market amassed USD 525.5 million in revenue in 2023. It is anticipated to experience a Compound Annual Growth Rate (CAGR) of 6.0% between 2024 and 2030, ultimately reaching USD 781.9 million by 2030. This growth can be credited to the increasing occurrence of gastrointestinal cancers and other peptic issues and the rising aging populace with gastrointestinal illnesses including diverticulosis and bowel sicknesses.
A major cause of death globally is stomach cancer which is a product of the gastrointestinal system. Most of the patients in recent years have been dying or sicker from chronic diseases such as colorectal cancer, esophageal cancer, and GI-related critical illnesses.
According to a new study released by the International Agency for Research on Cancer (IARC) in July 2020, colorectal cancer took away 35% of all deaths and 26% of all new incidences on the global map, and in 2018, IARC cites that there were approximately 4.8 million of colon cancer sufferers and 3.4 million
Furthermore, the increasing prevalence of Crohn's disease in all socio-economic sections of society stands behind the demand. As indicated by the Crohn's & Colitis Foundation, in 2020, three-quarters of all patients with Crohn's disease had one or more procedures at some point in their history.
Key Insights
In 2023, the biliary stent category had the largest income share of 35%.
It is projected to uphold its supremacy because of the growing occurrence of obstructive jaundice, which can outcome from malignant or benign disease.
Biliary stents are utilized to cure obstructions in the biliary tree or biliary leaks.
Minimally invasive endoscopic stent placement is now the most effective treatment choice for serious benign bile duct strictures.
The Self-expanding metal stents category had the largest share of 40% in the industry.
They are projected to uphold supremacy because of benefits such as high effectiveness, lengthier potency, ease of insertion, and low migration or dislodgment risk.
Such stents are utilized for handling benign gastrointestinal leaks and perforations.
Metal stents are characteristically made of nitinol, stainless steel, and cobalt-chromium, offering backing to keep the GI tract open for unobstructed drainage.
The drug-eluting stent category had a larger revenue share in the gastrointestinal stent market in 2023.
In 2023, the drug-eluting stent category generated a larger revenue share in the gastrointestinal stent industry.
The category is also projected to uphold its supremacy because of benefits such as decreased target-vessel revascularization and reduced danger of associated diseases.
Such stents efficiently release medication and have seen improvements like biodegradability.
The slow release of medicine is a major advantage contributing to the efficiency of drug-eluting stents.
In 2023, the North American region had the largest revenue share of approximately 50%, with prospects of strong CAGR development over the projection period.
Reasons propelling this include high disposable income, healthcare spending, a huge aging populace with gastrointestinal problems, and a high acceptance rate of minimally invasive operations.
The region's market growth will be driven by the existence of an ideal after-payment structure and the emergence of new cases of GI diseases as well.
The Canadian market looks very promising because the emerging medical equipment infrastructure, government initiatives, as well as the high demand for minimally invasive surgeries, are the factors contributing to this development.
The vast European market is anticipated to demonstrate high growth powered by the growing healthcare infrastructure advancements, as well as the increase in the number of chronic diseases and favorable reimbursement policies.